AMYLOIDOSIS RESEARCH CONSORTIUM INC (EIN 472589708) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

ISABELLE LOUSADA

Phone

6178998810

Tax Period

2023-01-01 to 2023-12-31

AMYLOIDOSIS RESEARCH CONSORTIUM INC, founded in 2015, is a community nonprofit in the Medical Research sector that reported $2.9M in total revenue in fiscal year 2023. Revenue surged 28% from the prior year, signaling strong growth momentum. The organization ran a surplus of $473K, a strong 16% operating margin.

Mission

ACCELERATING THE DEVELOPMENT OF ADVANCED DIAGNOSTIC TOOLS AND EFFECTIVE TREATMENTS FOR SYSTEMIC AMYLOIDOSIS THROUGH COLLABORATION AND INNOVATION.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $2,702,741

Program Service Revenue $1,525

Investment Income $54,751

Other Revenue $129,008

TOTAL REVENUE $2,888,025

Expense Breakdown

Grants Paid $0

Salaries & Benefits $1,497,962

Fundraising Expenses $524,772

Program Expenses $1,548,608

Other Expenses $917,097

TOTAL EXPENSES $2,415,059

Year-over-Year Comparison

	2023	2022	Change
Revenue	$2,888,025	$2,260,256	+0.3%
Expenses	$2,415,059	$2,129,932	+0.1%
Net Income	$472,966	$130,324	+2.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$178,365

Total Directors

$178,365

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ISABELLE LOUSADA	PRESIDENT/CEO & SECRETARY	40.00	Officer Director	$178,365	$0	$178,365
SARAH CAIRNS-SMITH	CHAIR	0.25	Officer Director	$0	$0	$0
RICK NATHANSON	BOARD MEMBER	0.25	Director	$0	$0	$0
DR RAYMOND COMENZO	BOARD MEMBER	0.25	Director	$0	$0	$0
JASON SHORE	TREASURER	0.25	Officer Director	$0	$0	$0
DENA HEATH	BOARD MEMBER	3.00	Director	$0	$0	$0
DR ASHUTOSH WECHALEKAR	BOARD MEMBER	0.25	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$2,888,025	$2,415,059	$2,975,266	$472,966
2022	$2,260,256	$2,129,932	$2,516,230	$130,324
2021	$1,647,972	$1,682,131	$2,350,923	$-34,159
2020	$2,125,459	$1,233,948	$2,277,557	$891,511
2019	$1,697,298	$1,328,269	$1,394,467	$369,029
2018	$1,416,444	$1,659,988	$1,548,310	$-243,544

AMYLOIDOSIS RESEARCH CONSORTIUM INC